Clinical Report: Early Treatment of Geographic Atrophy with Complement Inhibition
Overview
Early identification and treatment of geographic atrophy (GA) with intravitreal complement inhibitors can stabilize vision and slow lesion progression. A 79-year-old patient with asymmetric GA demonstrated stable visual acuity over 2+ years of treatment, highlighting the importance of timely intervention and long-term therapy commitment.
Background
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration characterized by progressive retinal atrophy leading to vision loss. Early detection of GA, especially nonsubfoveal lesions with preserved central vision, offers a critical window for therapeutic intervention. Complement inhibition has emerged as an FDA-approved treatment to slow GA progression. Managing asymmetric bilateral GA requires careful monitoring to determine the optimal timing for treatment initiation in each eye.
Data Highlights
| Parameter | Right Eye (OD) | Left Eye (OS) |
|---|---|---|
| Baseline BCVA | 20/40 | 20/40 |
| GA Status at Baseline | Moderate multifocal nonsubfoveal GA with hyperautofluorescent borders | Large central drusen, mild atrophy |
| Treatment Initiation | Nov 2023 | Apr 2025 |
| Treatment Duration | >2 years | 9 months |
| Visual Acuity at Follow-up | Stable at 20/40 | Stable at 20/40 |
| GA Progression | Continued enlargement with preserved central foveal island | Early central GA detected prompting treatment |
| Adverse Events | None observed | None observed |
Key Findings
- Early treatment of nonsubfoveal GA with complement inhibitors preserves central vision and slows lesion growth.
- Monitoring asymmetric GA allows for staged treatment initiation, optimizing timing based on disease progression.
- Long-term commitment to bi-monthly intravitreal injections is essential for sustained therapeutic benefit.
- Prior pars plana vitrectomy did not negatively impact treatment efficacy over 2 years.
- Visual acuity remained stable at 20/40 bilaterally despite ongoing peripheral GA progression.
- Complement inhibition therapy was well tolerated with no adverse events reported.
Clinical Implications
Retina specialists should prioritize early detection of nonsubfoveal GA with preserved foveal islands to initiate complement inhibitor therapy within the optimal treatment window. Regular imaging and monitoring are critical to identify progression, especially in asymmetric cases, to time treatment initiation appropriately. Patient education on the importance of long-term adherence to bi-monthly injections is vital to maximize clinical benefits.
Conclusion
This case exemplifies how early, targeted complement inhibition in GA patients with preserved central vision can stabilize visual function and slow disease progression. Tailored treatment strategies based on disease asymmetry and progression optimize patient outcomes in geographic atrophy management.
References
- London N. 2023-2025 -- Case Study: Early Treatment of Geographic Atrophy
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.